Purpose Mean heart dose (MHD) correlates with late cardiac toxicity among survivors of
lymphoma receiving involved-field radiation therapy (IFRT). We investigated MHD and …

Purpose Mediastinal radiation therapy (RT) for Hodgkin lymphoma (HL) is associated with
late cardiotoxicity, but there are limited data to indicate which dosimetric parameters are …

Purpose Patients with lower mediastinal lymphoma (LML) benefit dosimetrically from proton
therapy (PT) compared with intensity modulated radiation therapy (IMRT). The added …

BACKGROUND AND PURPOSE: To increase heart and coronary artery protection in
patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy …

PURPOSE: We investigated the dosimetric impact of proton therapy (PT) on various cardiac
subunits in patients with Hodgkin lymphoma (HL). METHODS AND MATERIALS: From June …

Background Hodgkin's lymphoma (HL) survivors who undergo radiotherapy experience
increased risks of second cancers (SC) and cardiac sequelae. To reduce such risks …

PURPOSE: To identify dose–heart-volume constraints that correlate with the risk of
developing asymptomatic valvular defects (VD) in Hodgkin's lymphoma (HL) patients treated …

Background Radiotherapy-related heart injury is well documented, with no apparent safety
threshold dose. The number of long-term cancer survivors exposed to mediastinal …

PURPOSE: Hodgkin lymphoma (HL) survivors are known to have increased cardiac
mortality and morbidity. The risk of developing cardiovascular disease after involved node …

Background Hodgkin lymphoma (HL) survivors have an increased morbidity and mortality
from secondary cancers and cardiovascular disease (CD). We evaluate doses with involved …